Ardelyx (ARDX) Q1 2026 earnings summary

Executive summary

• Achieved Q1 2026 total product revenue of $93.4 million, a 38% year-over-year increase, driven by strong demand for IBSRELA (up 58% to $70.1 million) and XPHOZAH ($23.3 million).

• Focused on four key priorities: accelerating IBSRELA growth, maintaining XPHOZAH momentum, expanding the pipeline (including Phase 3 trial for CIC and RDX10531), and delivering strong financial results.

• Maintained financial flexibility with $238.1 million in cash, cash equivalents, and short-term investments as of March 31, 2026.

• Net loss for Q1 2026 was $37.6 million ($0.15/share), improved from $41.1 million ($0.17/share) in Q1 2025.

• Added new executive talent and expanded leadership to support legal, medical, and commercial operations.

Financial highlights

• Q1 2026 total product revenues reached $93.4 million, up from $67.8 million in Q1 2025 (38% growth); net product sales rose 38% year-over-year.

• IBSRELA revenue was $70.1 million, a 58% increase year-over-year; XPHOZAH revenue was $23.3 million, flat year-over-year as reported, but paid prescriptions grew 19%.

• R&D expenses rose to $20.2 million (from $14.9 million), reflecting increased development and clinical trial activity.

• SG&A expenses increased to $102.3 million (from $83.2 million), supporting commercialization and infrastructure.

• Gross-to-net (GTN) rate blended at 36.4% in Q1, reflecting channel mix and rebates.

Outlook and guidance

• Reiterated 2026 revenue guidance: IBSRELA $410–$430 million (50–57% growth), XPHOZAH $110–$120 million.

• Long-term target for IBSRELA: at least $1 billion in annual revenue by 2029 (38% CAGR); XPHOZAH long-term revenue target reaffirmed at $750 million.

• Full-year product revenue expected to grow 38–46%, outpacing operational expense growth (~25%).

• Total 2026 OpEx guided to ~$520 million, with ramp-up expected as clinical trial enrollment progresses.

• Expects to complete enrollment in the Phase 3 CIC trial by end of 2026, with topline data in H2 2027.